14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Lipid Based Antigen Delivery System Efficiently Facilitates MHC Class-I Antigen Presentation in Dendritic Cells to Stimulate CD8 + T Cells

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The most effective strategy for protection against intracellular infections such as Leishmania is vaccination with live parasites. Use of recombinant proteins avoids the risks associated with live vaccines. However, due to low immunogenicity, they fail to trigger T cell responses particularly of CD8 + cells requisite for persistent immunity. Previously we showed the importance of protein entrapment in cationic liposomes and MPL as adjuvant for elicitation of CD4 + and CD8 + T cell responses for long-term protection. In this study we investigated the role of cationic liposomes on maturation and antigen presentation capacity of dendritic cells (DCs). We observed that cationic liposomes were taken up very efficiently by DCs and transported to different cellular sites. DCs activated with liposomal rgp63 led to efficient presentation of antigen to specific CD4 + and CD8 + T cells. Furthermore, lymphoid CD8 + T cells from liposomal rgp63 immunized mice demonstrated better proliferative ability when co-cultured ex vivo with stimulated DCs. Addition of MPL to vaccine enhanced the antigen presentation by DCs and induced more efficient antigen specific CD8 + T cell responses when compared to free and liposomal antigen. These liposomal formulations presented to CD8 + T cells through TAP-dependent MHC-I pathway offer new possibilities for a safe subunit vaccine.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: not found

          The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

          The inflammatory toxicity of lipopolysaccharide (LPS), a component of bacterial cell walls, is driven by the adaptor proteins myeloid differentiation factor 88 (MyD88) and Toll-interleukin 1 receptor domain-containing adapter inducing interferon-beta (TRIF), which together mediate signaling by the endotoxin receptor Toll-like receptor 4 (TLR4). Monophosphoryl lipid A (MPLA) is a low-toxicity derivative of LPS with useful immunostimulatory properties, which is nearing regulatory approval for use as a human vaccine adjuvant. We report here that, in mice, the low toxicity of MPLA's adjuvant function is associated with a bias toward TRIF signaling, which we suggest is likely caused by the active suppression, rather than passive loss, of proinflammatory activity of this LPS derivative. This finding may have important implications for the development of future vaccine adjuvants.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Applications of nanotechnology for immunology

            Key Points Nanotechnology makes use of the unique properties of objects that function as a unit within the overall size range of 1 to 1,000 nanometres, which is on the same scale as for many biological structures such as antigens, receptors, subcellular components of the immune system and microbes. The engineering of nanoscale compounds by the modification of properties such as nanoparticle size, shape, charge, porosity, surface area and hydrophobicity holds great promise for the development of immune response modulators and vaccines. The enhancement of the immune response by nanoparticles can be achieved through innate immune potentiation or by the enhanced delivery of antigens. Virus-like particles activate the innate immune response via Toll-like receptors and the repetitive display of antigens, whereas nanogels and cationic liposomes are examples of vaccine carriers. The molecular pathways involved in immune activation by nanoparticles are diverse and might include the upregulation of homing receptors such as CC-chemokine receptor 7, co-stimulatory molecules including CD40, CD80 and CD86, as well as increased cytokine production. Enhanced delivery by nanoparticles might induce apoptosis or necrosis. The suppression of the immune response can be achieved through direct immunosuppression or by the delivery of immunosuppressants. Fullerenes have a direct immunosuppressive effect but can also deliver immunosuppressive drugs, as can dendrimers, polymers, and liposomes. The molecular pathways involved in immunosuppression might include increased expression of cyclooxygenase 2, prostangandin E2 and interleukin-10 (IL-10), and apoptosis. The delivery of immunosuppressants results in a decreased response to IL-2 with sirolimus, in the downregulation of nuclear factor-kB with steroids, and in the upregulation of forkhead box P3 (FOXP3), which causes an increased regulatory T cell activity when self antigens are presented. Nanotechnology will continue to provide remarkable insights into the nature of the immune response. The application of nanotechnology to immunology might also affect new strategies to prevent or to treat human diseases. Supplementary information The online version of this article (doi:10.1038/nri3488) contains supplementary material, which is available to authorized users.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              New horizons in adjuvants for vaccine development.

              Over the last decade, there has been a flurry of research on adjuvants for vaccines, and several novel adjuvants are now in licensed products or in late stage clinical development. The success of adjuvants in enhancing the immune response to recombinant antigens has led many researchers to re-focus their vaccine development programs. Successful vaccine development requires knowing which adjuvants to use and knowing how to formulate adjuvants and antigens to achieve stable, safe and immunogenic vaccines. For the majority of vaccine researchers this information is not readily available, nor is access to well-characterized adjuvants. In this review, we outline the current state of adjuvant research and development and how formulation parameters can influence the effectiveness of adjuvants.
                Bookmark

                Author and article information

                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group
                2045-2322
                02 June 2016
                2016
                : 6
                : 27206
                Affiliations
                [1 ]Indian Institute of Chemical Biology, Infectious Diseases and Immunology Division , 4, Raja S.C. Mullick Road, Jadavpur, Kolkata-700032, India
                Author notes
                [*]

                Present address: Premas Biotech Pvt Ltd, Plot No: 77, Sector 4, IMT Manesar, Gurgaon, Haryana-122050, India.

                [†]

                Present address: University of Texas Southwestern Medical Center, Department of Radiation Oncology, Division of Molecular Radiation Biology, Dallas, Texas, USA.

                Article
                srep27206
                10.1038/srep27206
                4890172
                27251373
                4ae718d2-2a4d-4d61-bcec-5a347fdd3625
                Copyright © 2016, Macmillan Publishers Limited

                This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

                History
                : 04 January 2016
                : 17 May 2016
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article